Abbvie Inc
NYSE:ABBV
Abbvie Inc
NYSE:ABBV
Price:
164.66 USD
0.25%
Market Closed
Updated:
Apr 19, 2024
Abbvie Inc
Cash from Operating Activities
Last
Value
3-Years CAGR
5-Years CAGR
|
Abbvie Inc
Cash from Operating Activities Peer Comparison
Comparables:
GILD
AMGN
VRTX
REGN
SGEN
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$8.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$4.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
|
Seagen Inc
NASDAQ:SGEN
|
Cash from Operating Activities
$-540.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
See Also
What is Abbvie Inc's Cash from Operating Activities?
Cash from Operating Activities
22.8B
USD
22.8B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Cash from Operating Activities amounts to 22.8B USD.
What is Abbvie Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
14%
14%
Over the last year, the Cash from Operating Activities growth was -8%. The average annual Cash from Operating Activities growth rates for Abbvie Inc have been 9% over the past three years , 11% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet
